Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31780-31791

  Liang, Weiwei ^a   Guan, Hongyu ^a   He, Xiaoying ^a   Ke, Weijian ^a   Xu, Lijuan ^a   Liu, Liehua ^a   Xiao, Haipeng ^a   Li, Yanbing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cyclin A2; Cyclin E2; Proliferation; SOSTDC1; Thyroid cancer

Indexed keywords

CYCLIN A2; CYCLIN E; CYCLIN E2; SCLEROSTIN; SOSTDC1 PROTEIN; UNCLASSIFIED DRUG; CCNA2 PROTEIN, HUMAN; CCNE2 PROTEIN, HUMAN; CYCLINE; MESSENGER RNA; PROTEIN; SOSTDC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; THYROID CANCER; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CANCER STAGING; CELL CYCLE; DRUG SCREENING; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYCLIN A2; CYCLINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945586679     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5566     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Russo D, Damante G, Puxeddu E, Durante C and Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol. 2011; 46:R73-81.
3. Nikiforov YE and Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011; 7:569-580.
4. Lintern KB, Guidato S, Rowe A, Saldanha JW and Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem. 2009; 284:23159-23168.
5. Kassai Y, Munne P, Hotta Y, Penttila E, Kavanagh K, Ohbayashi N, Takada S, Thesleff I, Jernvall J and Itoh N. Regulation of mammalian tooth cusp patterning by ectodin. Science. 2005; 309:2067-2070.
6. Beaudoin GM, 3rd, Sisk JM, Coulombe PA and Thompson CC. Hairless triggers reactivation of hair growth by promoting Wnt signaling. Proc Natl Acad Sci U S A. 2005; 102:14653-14658.
7. Collette NM, Yee CS, Murugesh D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM and Loots GG. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. Dev Biol. 2013; 383:90-105.
8. Shigetani Y, Howard S, Guidato S, Furushima K, Abe T and Itasaki N. Wise promotes coalescence of cells of neural crest and placode origins in the trigeminal region during head development. Dev Biol. 2008; 319:346-358.
9. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB, Jr., Miller LD, Torti FM and Torti SV. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat. 2011; 129:737-746.
10. Blish KR, Wang W, Willingham MC, Du W, Birse CE, Krishnan SR, Brown JC, Hawkins GA, Garvin AJ, D'Agostino RB, Jr., Torti FM and Torti SV. A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell. 2008; 19:457-464.
11. Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H and Kaneko Y. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer. 2009; 48:1037-1050.
12. Rajkumar T, Vijayalakshmi N, Gopal G, Sabitha K, Shirley S, Raja UM and Ramakrishnan SA. Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int. 2010; 10:45.
13. Gopal G, Raja UM, Shirley S, Rajalekshmi KR and Rajkumar T. SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer. Cancer Genet. 2013; 206:174-182.
14. Manning AL and Dyson NJ. RB: mitotic implications of a tumour suppressor. Nat Rev Cancer. 2012; 12:220-226.
15. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995; 81:323-330.
16. Gordon GM and Du W. Conserved RB functions in development and tumor suppression. Protein Cell. 2011; 2:864-878.
17. Singh S, Johnson J and Chellappan S. Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim Biophys Acta. 2010; 1799:788-794.
18. Blish KR, Clausen KA, Hawkins GA, Garvin AJ, Willingham MC, Turner JC, Torti FM and Torti SV. Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors. J Exp Clin Cancer Res. 2010; 29:147.
19. Barderas R, Mendes M, Torres S, Bartolome RA, LopezLucendo M, Villar-Vazquez R, Pelaez-Garcia A, Fuente E, Bonilla F and Casal JI. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics. 2013; 12:1602-1620.
20. Rawat A, Gopisetty G and Thangarajan R. E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells. Cell Oncol (Dordr). 2014; 37:409-419.
21. Gong D, Pomerening JR, Myers JW, Gustavsson C, Jones JT, Hahn AT, Meyer T and Ferrell JE, Jr. Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1. Curr Biol. 2007; 17:85-91.
22. Zhong WB, Hsu SP, Ho PY, Liang YC, Chang TC and Lee WS. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol. 2011; 82:1663-1672.
23. Yasmeen A, Berdel WE, Serve H and Muller-Tidow C. E-and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2003; 3:617-633.
24. Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO and Coats S. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999; 19:612-622.
25. Payton M, Scully S, Chung G and Coats S. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene. 2002; 21:8529-8534.
26. Caldon CE, Sergio CM, Schutte J, Boersma MN, Sutherland RL, Carroll JS and Musgrove EA. Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol. 2009; 29:4623-4639.
27. Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, Azambuja E, Paesmans M, Larsimont D, Buyse M, Harris A, Piccart M, Martiat P and Sotiriou C. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer. 2006; 119:2539-2545.
28. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG and Foekens JA. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res. 2006; 12:3319-3328.
29. Zhao Z, Liu J, Wang C, Wang Y, Jiang Y and Guo M. MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2. Int J Clin Exp Pathol. 2014; 7:7726-7734.
30. Gordon GM and Du W. Targeting Rb inactivation in cancers by synthetic lethality. Am J Cancer Res. 2011; 1:773-786.
31. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M and Hoffman RM. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008; 68:516-520.
32. Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J and Li M. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer. 2012; 130:593-601.
33. Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao H, Li M and Li Y. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab. 2013; 98:E1334-1344.
34. Guan H, Liang W, Liu J, Wei G, Li H, Xiu L, Xiao H and Li Y. Transmembrane Protease Serine 4 Promotes Thyroid Cancer Proliferation via CREB Phosphorylation. Thyroid. 2014.
35. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-1068.
36. Bracken AP, Ciro M, Cocito A and Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci. 2004; 29:409-417.